Developing new methods for creating complex organic molecules
Novel Transition Metal Catalysis for Chemical Synthesis
['FUNDING_OTHER'] · UNIVERSITY OF TEXAS DALLAS · NIH-11011701
This study is exploring a new way to make important changes to organic molecules that are used in medicines, using light to make the process easier and safer, which could help create drugs more efficiently and affordably.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS DALLAS (nih funded) |
| Locations | 1 site (RICHARDSON, UNITED STATES) |
| Trial ID | NIH-11011701 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a new platform for the selective functionalization of organic molecules, which are essential for drug development. By utilizing non-functionalized substrates, the research aims to simplify the process of modifying complex biologically important molecules. The approach involves a novel catalytic methodology that uses visible light to enable controlled reactions without the need for harsh conditions or external oxidants. This could lead to more efficient and cost-effective methods for synthesizing pharmaceuticals.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals involved in pharmaceutical development or those requiring novel drug formulations.
Not a fit: Patients who are not involved in drug development or do not require new pharmaceutical interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance the efficiency of drug discovery and development processes.
How similar studies have performed: While the approach is innovative, similar methodologies in catalysis have shown promise in other contexts, suggesting potential for success.
Where this research is happening
RICHARDSON, UNITED STATES
- UNIVERSITY OF TEXAS DALLAS — RICHARDSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GEVORGYAN, VLADIMIR — UNIVERSITY OF TEXAS DALLAS
- Study coordinator: GEVORGYAN, VLADIMIR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.